PRINCETON, N.J., May 8 /PRNewswire-FirstCall/ -- Covance Inc. (NYSE:
CVD) today announced that it has elected Joseph C. Scodari to its Board of
Directors.
"We are very pleased to have Joe Scodari join our Board of Directors.
He has enjoyed a distinguished 34-year career as a key leader in the
pharmaceutical and biotechnology industries, and he has a proven track
record of driving growth in large, complex global healthcare businesses,"
said Joe Herring, Covance chairman and CEO. "In addition, Mr. Scodari's
expertise in strategy development and pharmaceutical R&D will help us
further strengthen our large client partnerships and enhance our ability to
provide productivity solutions that matter."
"Covance's market leadership and broad service offerings position it
well to help pharmaceutical companies reduce the time and cost of drug
development," Mr. Scodari said. "I look forward to working with Joe and the
esteemed group of board members to take advantage of the significant market
opportunities in the drug development services industry and continue to
drive the company's growth."
Mr. Scodari was recently the worldwide chairman of the Johnson &
Johnson (J&J) Pharmaceuticals Group. In this role, he led efforts to
improve research and development productivity and build a more robust
pipeline. He was also a member of the J&J executive committee and a
corporate officer. Before Mr. Scodari was appointed worldwide chairman of
J&J's pharmaceutical business in 2005, he was the company group chairman of
J&J's global biopharmaceuticals business and was responsible for commercial
activities in biotechnology and for specialty businesses in oncology and
virology. Under his leadership, Tibotec Therapeutics launched PREZISTA(R)
(darunavir), the company's first entry into the HIV market. Previously, Mr.
Scodari served as company group chairman for the North America
pharmaceuticals business, which included management responsibility for
Ortho-McNeil, Janssen Pharmaceutica, and Janssen-Ortho Inc., Canada. Prior
to these roles, he served as president and COO, and as a director of
Centocor, Inc. and led the organization's transformation from a focus on
research and development to a fully integrated biopharmaceutical company.
Mr. Scodari has also held leadership positions in Rhone-Poulenc Rorer
Pharmaceuticals and Sterling Drug, Inc.
Mr. Scodari recently served as the vice chairman of the board and
member of the executive committee of the Biotechnology Industry
Organization (BIO). He has also served on the Board of Overseers of the
Robert Wood Johnson School of Medicine and on the Board of Trustees of The
University of the Sciences in Philadelphia. He was also previously a member
of the Board of Directors of Pharmacyclics, Inc., a biopharmaceutical
company focused on therapies for cancer. He has a B.A. from Youngstown
State University.
Covance, with headquarters in Princeton, New Jersey, is one of the
world's largest and most comprehensive drug development services companies
with annual revenues greater than $1.5 billion, global operations in more
than 20 countries, and more than 8,900 employees worldwide. Information on
Covance's products and services, recent press releases, and SEC filings can
be obtained through its website at http://www.covance.com.
SOURCE Covance Inc.
 back to top
Related links:
http://www.covance.com/
CONTACT:
Covance Inc., Media: +1-609-419-2060, or
Investors: +1-609-452-4807
|
